Bioptimus Unveils M-Optimus, a World Model for Biology
Revolutionary model represents a transformative step toward AI-powered virtual tissues, patient digital twins, and a new era of data-driven biomedical...
Pharmaceutical
Hidden Work and Shadow AI Are Driving Health System AI Pilots, New Findings Show
Black Book Market Research finds fewer than 1 in 5 health systems report mature AI governance and most undercount staff...
Medical Care Technologies, Inc. (OTC Pink:MDCE) Announces Completion of AI-Based Consumer App, Now in iOS App Store Review
MESA, ARIZONA / ACCESS Newswire / December 17, 2025 / Medical Care Technologies, Inc. (OTC Pink:MDCE) is pleased to announce...
Saint Therese Launches Educational Series to Help Adult Children Navigate Aging Before a Crisis
New series helps adult children plan ahead before decisions become urgent SAINT LOUIS PARK, MN / ACCESS Newswire / December...
Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell
RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing...
Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell
RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing...
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026
PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics...
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026
PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics...
Alira Health Appoints Dr. Susanne Schaffert as Senior Advisor and Patient-Centric Ambassador
FRAMINGHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Alira Health, a global advisory firm and CRO, today announced the appointment...
Alira Health Appoints Dr. Susanne Schaffert as Senior Advisor and Patient-Centric Ambassador
FRAMINGHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Alira Health, a global advisory firm and CRO, today announced the appointment...
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s...
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s...
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of AtlantaResults demonstrated...
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of AtlantaResults demonstrated...
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel...
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel...
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all...
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all...
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for...
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for...